Single dose of LSD-based drug shows significant depression relief in key Phase 3 trial
A single-dose LSD-based drug has just cleared one of medicine’s highest evidentiary bars — offering meaningful, durable relief from major depressive disorder in a rigorous Phase 3 trial. DT120 ODT, a pharmaceutically refined lysergide compound, produced an 8.1-point improvement on the standard depression scale compared to placebo, with nearly all side effects mild and resolving the same day. For the millions who cycle through daily antidepressants without real relief, a single-dose model represents a genuinely different kind of hope — and a signal that psychedelic-assisted medicine is maturing into a serious contender in mainstream psychiatric care.









